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Abstract
Background: With recent advances in microarray technology, including genomics, proteomics, and metabolomics, it
brings a great challenge for integrating this “-omics” data to analysis complex disease. Glioma is an extremely
aggressive and lethal form of brain tumor, and thus the study of the molecule mechanism underlying glioma remains
very important. To date, most studies focus on detecting the differentially expressed genes in glioma. However, the
meta-analysis for pathway analysis based on multiple microarray datasets has not been systematically pursued.
Results: In this study, we therefore developed a systems biology based approach by integrating three types of
omics data to identify common pathways in glioma. Firstly, the meta-analysis has been performed to study the
overlapping of signatures at different levels based on the microarray gene expression data of glioma. Among these
gene expression datasets, 12 pathways were found in GeneGO database that shared by four stages. Then,
microRNA expression profiles and ChIP-seq data were integrated for the further pathway enrichment analysis. As a
result, we suggest 5 of these pathways could be served as putative pathways in glioma. Among them, the
pathway of TGF-beta-dependent induction of EMT via SMAD is of particular importance.
Conclusions: Our results demonstrate that the meta-analysis based on systems biology level provide a more useful
approach to study the molecule mechanism of complex disease. The integration of different types of omics data,
including gene expression microarrays, microRNA and ChIP-seq data, suggest some common pathways correlated
with glioma. These findings will offer useful potential candidates for targeted therapeutic intervention of glioma.
Background
In the last few years, the post-human genome project
era is coming, which has witnessed the evolution of
multi-level omics data, including genomics, proteomics,
and metabolomics. As more and more microarray data-
sets and technologies development, they have gradually
become standard resources and tools to analysis com-
plex disease. On the other hand, cancer is a complex
biological system and thus its molecular mechanism
needs to be understood at systems-level [1,2]. As a most
recent development, micro-RNA (miRNA) not only has
promising clinical applications in cancer diagnosis and
treatment, but also could as competing endogenous
RNAs (ceRNA) to construct a regulation network to
understand regulatory pathways in cancer [3]. Therefore,
the meta-analysis [4] of cancer by integrating omics data
at the systems biology level is of significant importance,
or at least, is possible.
Brain tumours are kind of complex cancer and high
leading cause of death in the United States. Glioma, the
most common type of primary brain tumours, which
occurs in the glical cells of adults [5,6]. According to their
histological types and World Health Organization (WHO)
grades [7], gliomas can be classified into several general
categories, for example glioblastomas multiforme (GBM)
belongs to a WHO grade IV tumor. Till now, most of
research effort has been directed at identification of
important genes in glioma. In 2010, Katara et al. [8] sug-
gested that CDK4, MDM2, EGFR, PDGFA, PDGFB and
PDGFRA genes can be served as biomarkers for glioma.
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In addition, they also found that CDKN2A, PTEN, RB1
and TP53 are the tumor suppressor genes. Li et al. [9]
found that ECRG4 is a down-regulated gene in glioma,
which has been reported as a candidate tumor suppressor
in other cancers. However, the study of molecular bias of
glioma at the system level is still needed [10].
In order to improve therapeutics of glioma, it will
require greater knowledge at both the genomic and
transcriptional level. Fortunately, recent advances show
that miRNA expression profiles provide valuable mole-
cular signatures for gliomas. Han et al. [11] reported
that miR-21 could enhance the chemotherapeutic effect
of taxol on human glioblastoma (GBM) U251 cells.
Chromatin immunoprecipitation followed by high-
throughput sequencing (ChIP-seq) technology has also
been applied to analysis GBM cells, such as identify glo-
bal SOX2 binding regions [12]. Token these data
together, it is possible to analyse the glioma at the sys-
tems biology level, from pathway level, network level,
and even to system network dynamics level.
In this paper, we aimed to analyze the molecular basis
of glioma at systems biology level, by integrating three
types of omics data, including gene expression microar-
ray, MicroRNA and ChIP-seq data sets. The novel sta-
tistical method, named Cancer Outlier Profile Analysis
(COPA) [13], was used to detect the significantly differ-
entially expressed genes. Furthermore, the pathway
enrichment analysis, Gene Set Enrichment Analysis
(GSEA) [14], and MAPE [4] approach were also per-
formed, and some possible pathways that may be related
to disease are found in glioma.
Results
Data collection
We have downloaded the raw gene expression data sets
on glioma from Gene Expression Omnius (GEO), a pub-
lic database at NCBI. The detailed information of these
four datasets is summarized in Table 1. According to
WHO standard, the gliomas were pathologically diag-
nosed to subtypes, which include 42 normal brain sam-
ples and 462 patient tumor samples.
Microarray statistical analysis for glioma datasets
It is well known that tumor heterogeneity is a generic
property for cancer including glioma, which will reflect
its evolutionary dynamics [15]. Traditional statistics,
such as t-statistic and SAM [16,17], will not work for
detecting multiple coexisting genes caused by the het-
erogeneity of cancer. In order to address this problem, a
novel but powerful method called COPA was used here
to meta-analyze the expressed gene datasets. Meta-ana-
lysis is a statistical technique to combine results from
several microarray studies, increasing the reliability and
robustness of results from individual studies. COPA is
proposed by MacDonald et al. [13] by adding a simple
test based on robust centering and scaling of the data to
standard statistical tests.
First of all, the samples were classified into two types:
Normal and Glioma, for the detection analysis in the fra-
mework of COPA. The glioma sample can be further
classified into several subgroups, and 12 groups in all
were selected for the COPA analysis. The numbers of sig-
nificant genes of all datasets were close at the value of
1.8, which was set as the COPA threshold to define the
‘outlier’ status in the cancer samples. The text-mining
searches in the Entrez PubMed database found that 853
out of 6306 (14%) genes were related to glioma.
Then the pathway enrichment analysis was performed
by mapping these differentially expressed genes to Gene-
GO’s MetaCore™, a manually curated and comprehen-
sive commercial database. MetaCore™ is the flapship
product of GeneGo, which acts an integrated software
suite for functional analysis of experimental data, such as
human protein-protein, protein-DNA and protein com-
pound interactions, metabolic and signalling pathways
for human, mouse and rat. Accordingly, a total of 213
pathways were emerged in GeneGO database, which
have p value less than 0.05. Figure 1 shows the GeneGO’s
Ontology categories of these 213 pathways. In particular,
48 pathways were related to developmental process, 41
pathways were relevant to immune response, as well as
19 pathways of them were associated with apoptosis and
survival.
Table 1 Information on microarray expression profiling data of glioma
Dataset Platform Sample Number Sample Information Gene Number
Normal Tumor
Astrocytic Glioblastomas Oligodendrogliomas
PA A OD OA
Data 1 HG-U95Av2 25 5 6 / 7 7 / 12625
Data 2 U133-Plus 2.0 Array 284 8 8 29 159 52 28 54675
Data 3 U133-Plus 2.0 Array 15 6 / / 8 1 / 54675
Data 4 U133-Plus 2.0 Array 180 23 / 26 81 50 / 54675
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In addition, pathway analysis (or gene set analysis) was
method for correlating the known microarray genes with
the defined genes from biological pathway databases. The
Gene Set Enrichment Analysis (GSEA) is an improved
pathway analysis, which was performed to judge which
gene set/pathway is significant among the datasets [14].
Herein, the C2 curated gene sets from the Molecular Sig-
nature Database (MSigDB) was selected as the gene set
annotations, and then we got 513 outlier gene sets with
p value less than 0.05.
Signature similarities at the system level are higher than
that at the gene level
As our pervious works proposed [18], the similarity of
signature at the pathway/gene set level is higher than
that at the gene level. In the same way, the overlapping
analysis both at the gene level and pathway/gene set level
was implemented. For the four datasets, 11 pairs of data-
sets could be comparable, according to the different
stages of the glioma. Comparisons of the overlapping
percentage among differentially expressed genes, path-
ways enriched by GeneGO’s database, and gene sets
enriched by GSEA are shown in Figure 2. The result
clearly showed that the consistency across studies was
higher at the pathway/gene set level than at the gene
level. The p-value for the difference of overlapping
between outlier genes and GeneGO’s enriched pathways
was 2.77e-07 by paired t-test. The overlapping of gene
sets evaluated by GSEA software indicated that 64% of
the pairwise data sets are more overlapped at the gene
set level than that at the gene level. Therefore, these two
analyses both verified our pervious hypotheses that men-
tioned in the beginning of this section.
Identification of novel pathways by pathway level meta-
analysis
From the above result, we knew that the overlapping of
the enriched pathways was much higher than that for
the individual gene. In comparison with the gene level,
the identified pathways at pathway level were predomi-
nantly more robust and closer to the phenotype of inter-
est. The number of enriched pathways obtained from
GeneGo in the four datasets classified by grades has
been compared, as shown in Figure 3. We found that 12
common pathways are shared by at least four stages, as
listed in Table 2. When checking the results in PubMed,
the top 6 pathways have been confirmed to be asso-
ciated with glioma.
Figure 1 GeneGO Ontology classification of 213 enriched pathways.
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Table 3 demonstrates the other six pathways that have
not been reported as glioma related pathways. For these
pathways, we further investigated the number of identi-
fied genes and all genes. As expected, some indirect
evidences ware also found to support our results. From
the Table 3, one can see that a large number of reported
expressed genes in these pathways were related to the
glioma (from 50% to 83%).
Meta-analysis for pathway enrichment
Most meta-analysis methods developed currently for
biomarker detection are just by combining genomic stu-
dies. By combining statistical significance at the gene
level and at the pathway level, MAPE is a novel kind of
meta-analysis approaches for pathway enrichment analy-
sis [4]. In our work, MAPE has been applied to analyze
the four gene expression datasets mentioned above to
further verify our hypothesis. The pathway database of
MAPE used in our study was GeneGO’s MetaCore™,
which could provide a better comparison with the results
in our previous study [18]. In order to uncover the
mechanism more accurately, we analyzed the data accord-
ing to WHO grades. Accordingly, 91 pathways were found
to be related to the glioma.
Figure 2 Comparisons of overlapping analysis. Bar plot of the percentage overlapping on gene and pathway/gene sets levels across 11
pairwise datasets. The blue bars stand for the percentage overlapping of differentially expressed genes, while red bars and green bars stand for
percentage overlapping of enriched pathways in GeneGO database and enriched gene sets in GSEA, respectively.
Figure 3 Number of enriched pathways overlapped by various
stages calculated based on GeneGO analysis. The column lines
described the number of enriched pathways that were overlapped
by one stage, at least one stage, at least two stages, at least three
stages, and at least four stages, respectively.
Table 2 The 12 GeneGO’s pathways shared by at least
four stages among datasets
Pathway Name Pubmed
Count*
Chemokines and adhesion 687
Cell cycle (generic schema) 1122
TGF, WNT and cytoskeletal remodeling 380
WNT signalling pathway.







Role of IAP-proteins in apoptosis 0
Regulation of G1/S transition (part 1) 0
NOTCH1-mediated pathway for NF-KB activity modulation 0
Regulation of epithelial-to-mesenchymal transition (EMT) 0
TGF-beta-dependent induction of EMT via SMADs 0
Non-genomic (rapid) action of Androgen Receptor 0
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Combined the results obtained from the gene expres-
sion data, 27 common pathways were found both from
microarray statistical analysis and meta-analysis. More-
over, the GeneGO’s pathway for two results shows the
same Ontology categories.
Cross-validation by integrating other omics data
In order to verify our results, other two types of omics
data were also integrated to analysis glioma. The discovery
of microRNAs [19] introduced a new dimension in the
understanding of how gene expression is regulated in
1993. MicroRNAs are a class of endogenous, single-
stranded non-coding RNAs of 18-25 nucleotides in length,
functioning as negative regulators of gene expression at
the post-transcriptional level. The dysregulation of miR-
NAs has been demonstrated to play critical roles in
tumorigenesis, either through inhibiting tumor suppressor
genes or activating oncogenes inappropriately [20-22]. In
particular, microRNA-21 (miR-21) has been reported to
enhance the chemotherapeutic effect of taxol on human
glioblastoma multiform cells [23]. For our purpose, three
miRNAs expression profiles were downloaded from the
GEO database, which are listed in Table 4. Owing to the
different platforms of the datasets, the probe sequences
were mapped to the miRBase (http://www.mirbase.org) by
Blast [24] tools for identifying the concordant miRNA
names. We again used the COPA package to detect the
differentially expressed miRNAs between the normal and
tumor samples. And the quantization of outlier extraction
was set with the default parameters. The target genes for
the significant miRNAs were predicted by four widely
web-based databases, i.e. TargetScan, miRanda [25], RNA-
hybrid [26], and TargetSpy [27]. These tools were based
on both miRNA sequences and 3’Untranslated Regions
(UTRs) of protein-coding mRNA sequences and the bind-
ing energy calculated by the minimum free energy for
hybridization. For deeper understanding target genes’ bio-
logical functions, we mapped these targets of each dataset
to GeneGO database for enriched biological pathways
identification, respectively.
According to three datasets of microRNAs data, 187
pathways were found to be associated with glioma when
p-value < 0.05 was considered statistically significant.
5 out of the top 6 potential novel glioma pathways found
in the gene expression profiles study also exit in micro-
RNAs results, as listed in Table 5. Therefore, we suggest
these 5 pathways would be putative novel glioma path-
ways. The GeneGO’s Ontology categories of these path-
ways show the same result with that of gene expression
datasets (Additional file 1).
ChIP-seq is another new technique for genome-wide
profiling of protein-DNA interactions, histone modifica-
tions, or nucleosomes [28,29]. In ChIP-seq, the DNA
fragments of interest are sequenced directly instead of
being hybridized on an array. Compared with ChIP-chip,
ChIP-seq offers significantly improved data with higher
resolution, less noise, and greater coverage. Currently,
this technology has been widely used to study transcrip-
tion factor binding sites [30], and can provide invaluable
information for studying gene regulation.
In our research, the ChIP-seq dataset (accession num-
ber GSM575227) from the study conducted by Fang [12]
was downloaded as reads aligned to the human genome
from the GEO database. Here, we detected significant
peaks of signal enrichment with two different peak call-
ers: MACS [31], SISSRs [32]. Default parameters were
used in each case. The MACS uses a sliding window to
scan the genome, and uses a locally estimated Poisson
rate for enrichment peak identification. MACS not only
found more peaks with fewer false positives, but also pro-
vided better binding resolution to facilitate downstream
motif discovery. SISSRS is a novel algorithm for precise
Table 3 The top 6 potential novel pathways (GeneGO) found from 4 datasets
Pathway Name Object Count Pubmed Count Percentage(%)
Role of IAP-proteins in apoptosis 31 28 90.32%
Regulation of G1/S transition (part 1) 38 34 89.47%
NOTCH1-mediated pathway for NF-KB activity modulation 34 22 64.70%
Regulation of epithelial-to-mesenchymal transition (EMT) 64 54 84.38%
TGF-beta-dependent induction of EMT via SMADs 35 30 85.71%
Non-genomic (rapid) action of Androgen Receptor 40 27 67.50%
Table 4 Information on microRNA expression profiling data of glioma
Country Platform Number (all) Sample information MicroRNA Number Publication Year
Normal Tumor
Italy DiSteBa_Homo sapiens_Glioblastoma miRNA 340_v1.0 74 37 37 340 2011.01
Italy TJU-Human-Mouse-MicroRNA-1.6k-v1.1 35 13 22 353 2005.09
USA Agilent 8 × 15K Human miRNA-specific microarray 34 10 24 1510 2009.12
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identification of binding sites from short reads generated
from ChIP-seq experiments. SISSRs uses the direction
and density of reads and the average DNA fragment
length to identify binding sites. It detects points in the
genome where the net difference between the forward
and reverse read counts in a moving window transforms
from positive to negative. It is more accurate, sensitive
and robust for binding site identification compared with
other approaches.
The overlapped significantly enriched peaks identified by
the two approaches were used for subsequent analysis. We
applied PeakAnalyzer [33] to assign the protein binding
sites to target genes. Then the pathway analysis by map-
ping the genes to GeneGO got 76 glioma pathways with
the 0.05 p-value. TGF-beta-dependent induction of EMT
via SMADs, as one of the five pathways shown in Table 5,
was surprisingly verified in the ChIP-seq analysis.
Lastly, we made a comparison among the pathways
detected from gene expression data, MicroRNA expres-
sion data and ChIP-seq data, and the result show that
14 common pathways have been found in all the three
different omics data (Additional file 2).
TGF-beta-dependent induction of EMT via SMADs
For the three types of “omic” data, one of the common
pathways named TGF-beta dependent induction of
EMT via SMADs was found. The pathway map for
TGF-beta-dependent induction of EMT via SMADs in
GeneGO is shown in Figure 4. Even in the same path-
way, the differentially expressed genes may locate at dif-
ferent places, which supported our hypothesis again.
Although such a pathway needs more biological experi-
ments, it represents a good candidate for further study.
The research result in the Entrez PubMed database
showed that there is not any report about this pathway,
so we check some identified important genes and build
a pathway map that contains important microRNA
information for the detail discussion. For example, Smad
interacting protein 1 (SIP1) [34], TGF-beta [35], and LIF
have been identified and play an essential role in glioma.
Based on the systems biology level, we think the map
with both gene and microRNA information from the
differentially expressed analysis will produce more useful
information. The pathway map, shown in Figure 5,
includes the information of microRNAs that regulate
genes. We hypothesize that microRNAs regulated some
important genes in the pathway, which may served as
biomarkers for glioma. Therefore, we searched these
interesting microRNAs in the Entrez PubMed database,
where some of them have been reported to be related
with glioma. For example, Accumulating evidence indi-
cates that miRNA expression can be used as a diagnos-
tic and prognostic marker for human cancers. In Jiang’s
study [36], their results suggest that miR-182 could be a
valuable marker of glioma progression and that high
miR-182 expression is associated with poor overall survi-
val in patients with malignant glioma. Zhang et al. [37]
reported that miR-221/222 expression was significantly
increased in high-grade gliomas compared with low-
grade gliomas, and positively correlated with the degree
of glioma infiltration. Therefore, the novel pathway,
TGF-beta-dependent induction of EMT via SMADs, may
play an important role to cause glioma occurrence.
Discussion
Cancer is a type of complex disease [1], which means it
caused by a combination of genetic perturbations, lifestyle
effect and personal behaviours. Uncovering the molecular
mechanisms of such complex disease, it requires a new para-
digm that study cancer at a systems biology level, such as
gene sets, dynamic network or pathway level. Till now, most
of works just focus on the identification of individual genes
which might play important roles in glioma carcinogenesis,
such as YKL-40 is a biomarker in the series of GBM by the
comparative expression patterns analysis [38]. In addition,
CDK4, MDM2, EGFR, PDGFA, PDGFB and PDGFRA
genes were suggested to be biomarkers for glioma, as well as
CDKN2A, PTEN, RB1 and TP53 are found as the glioma
suppressor genes. Despite of these known genes for glioma,
the pathway analysis explore how genes interaction in a
pathway to play their function. To this aim, we tried to find
some new potential pathways based on the meta-analysed
four gene expression profiling datasets on glioma.
Another additional difficulty of studying cancer relates
of its heterogeneity at the molecular level. In heteroge-
neous disease, particular tumor, different cases will typi-
cally have different genes. Gene expression microarrays
measure thousands of genes simultaneously; therefore,
common statistical methods such as t-test will not work
for finding these genes. The common significant gene
analysis based on t-test or t-test like statistics methods
have been used to study special genetic changes in glioma
[39], and to identify some differentially expressed genes
associated with glioma [40]. Fortunately, COPA, a novel
method, has proven to be an effective approach to dis-
cover mechanisms underpinning heterogeneity in cancers
by combined with pathway and functional analysis. We
used COPA to identify the differentially expressed genes
Table 5 The top 5 novel GeneGO’s pathways overlapped
by gene and miRNA expression profiles
Pathway
Regulation of G1/S transition (part 1)
NOTCH1-mediated pathway for NF-KB activity modulation
Regulation of epithelial-to-mesenchymal transition (EMT)
TGF-beta-dependent induction of EMT via SMADs
Non-genomic (rapid) action of Androgen Receptor
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between glioma and normal samples in this study and
then detected enriched gene sets and pathways via GESA
tool and GeneGO’s MetaCore™ software.
This pathway study was complemented with additional
information including microRNA and ChIP-seq profiles.
MicroRNAs analysis has rapidly become an attractive
method for cancer research as it exhibits more accurate
and sensitive compared with traditional gene expression
profiling of mRNAs [41]. Accumulating evidence sug-
gests some miRNAs play an important role in glioma
occurrence. Han’s study [11] demonstrated that b-
catenin pathway regulates miR-21 expression via STAT3
playing a role in human glioma cell. Nowadays, with the
decreasing cost of sequencing, ChIP-seq has become a
useful tool for studying gene regulation and epigenetic
mechanisms. ChIP-seq offers significantly improved data
with higher resolution, less noise. Fang’s work [12]
demonstrated that SOX2 plays an important role in the
carcinogenesis and development of glioma. And the tar-
get genes for SOX2 binding regions in glioma cells were
identified, such as ARRDC4, PDE4D, BASP1 and so on.
In our work, microRNA expression profiles and ChIP-
Figure 4 GeneGo graphic illustration of TGF-beta-dependent induction of EMT via SMADs pathway. The differentially expressed genes
identified from the 12 groups of two-class are represented with red bar histograms. The numerical and alphabetic subscript represents the
datasets to which the gene belongs.
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seq data were integrated for the further verification. In
comparison with the results from gene expression data-
sets, five novel glioma related pathways were also identi-
fied in these datasets. Within these pathways, some of
them have already been reported as important pathways
in glioma. By controlling transcription of the cyclin-
dependent kinase inhibitor p27 (kip1), FOXO3a inhibits
cell-cycle progression at the G1/S transition, which is fre-
quently down-regulated in tumor cancers, such as human
glioma. NF-kB is previously reported as a transcription
factor, which controls expression of several oncogenes,
growth factors and cell adhesion molecules and plays a
key role in carcinogenesis [42-44]. Moreover, Li et al. [9]
found that ECRG4 serves as a tumor suppressor in
glioma in the NF-B pathway, which was supposed to be
included in glioma cell growth suppression.
In conclusion, we proposed a novel meta-analysis based
on systems biology level for cancer research and some
putative novel pathways were found to be associated with
glioma. Compared to previous analyses, our novel
approach integrated three types of “omics” data including
gene expression data, MicroRNA expression data and
ChIP-seq data, which could perform cross-validation each
other at the systems biology level, and thus the method is
both possible and necessary to decrease the discrepancy
and improve the understanding of the complex molecular
mechanisms underlying cancer. The novel pathway, TGF-
beta-dependent induction of EMT via SMADs, was found
in all the profiling, and thus could serve as a candidate
pathway for further experiment testing. We believed that
the developed method and the identified new pathway in
our work will provide more useful and detailed informa-
tion for future studies at the system level.
Conclusions
Systems biology provides powerful tools for the study of
complex disease. System-based approach verified the
idea that the overlapping of signatures is higher at the
pathway or gene set level than that at the gene level.
We have performed a pathway enrichment analysis by
Figure 5 A map for the key genes with microRNA information extracted from TGF-beta-dependent induction of EMT via SMADs
pathway. The differentially expressed genes identified from the pathway are represented by rectangle and oval, the red one denotes the TF,
the dark blue one denotes receptors with enzyme activity, and the green one denotes receptor ligand. In addition, the rectangles with arrows
means the microRNA that regulates the gene, and the ones reported as biomarkers are highlight with red color.
Hu et al. BMC Systems Biology 2013, 7(Suppl 2):S9
http://www.biomedcentral.com/1752-0509/7/S2/S9
Page 8 of 11
using GeneGo database, GSEA and MAPE software to
show several novel glioma pathways. In addition, 5 out
of these novel pathways have also been verified by inte-
grating a wealth of miRNAs expression profiles and
ChIP-seq data sets, thus, some good candidates for
further study. This story would mark a beginning, not
an end, to identify novel pathways of complex cancer
based on systems level. Two valuable future directions
would be rooted in the complexity and the heterogene-
ity of cancer. With the development of high-throughput
technologies, more and more data should be considered
and correlated at the level of systems biology. As was
discussed in text, although many meta-analysis techni-
ques and pathway enrichment analysis methods have
been developed in the past few years, a more robust
method by incorporating and evaluating these available
methods is also needed immediately.
Methods
Dataset
We collected four publicly available glioma microarray
expression datasets, which were performed using
Affymetrix oligonucleotide microarray. All the datasets
were generated by four independent laboratories. To
obtain more consistent results, we proposed to meta-
analyze the multiple microarrays. Rhodes et al. [45] indi-
cated that multiple datasets should be meta-analyzed
based on the same statistical hypothesis such as cancer
versus normal tissue, high grade cancer versus low
grade cancer, poor outcome cancer versus good out-
come cancer, metastasis versus primary cancer, and sub-
type 1 versus subtype 2. Therefore, our meta-analysis on
the basis of two types of samples, normal brain and
glioma tissues, were comparable. The individual analysis
of each dataset mainly includes three steps: pre-proces-
sing, differential expression analysis and pathway/gene
set enrichment analysis. Most analysis processes were
performed in R programming environment.
Data pre-processing
The raw datasets measured with Affymetrix chips were
analyzed using MAS5.0 [46] algorithm. We performed
Median Absolute Deviation (MAD) method [47] for
between-chip normalization of all datasets. Low-qualified
genes were eliminated and the filter criterion was defined
as 60% absence across all of the samples.
Differential expression analysis
Cancer Outlier Profile Analysis (COPA) method was
used for detecting differentially expressed genes between
normal and tumor samples. The copa [11] package was
implemented in R environments. Two steps of COPA
statistic is defined as following: 1) the data was centered
and scaled on a rowwise basis using median and median
absolute deviation. The columns of microarray expres-
sion data matrix were samples and the rows were genes.
2) The data in the disease group was pre-filtered by set-
ting the pre-filtration threshold as defaulted 95th percen-
tile. It means that the genes with a number of outlier
samples less than the 95th percentile were removed from
further consideration. A threshold cut-off for ‘outlier’ sta-
tus was set and applied to all genes.
Pathway and gene set enrichment analysis
After COPA analysis, the interested genes were mapped
to GeneGO database by MetaCore™ for pathway
enrichment analysis. It is a most comprehensive and
detailed human metabolism and signalling database [48].
In MetaCore™, the statistical significance (p-value)
represents the probability to randomly obtain the inter-
section of certain size between two gene/protein data-
sets following hyper geometric distribution.
Additionally, we applied Gene Set Enrichment Analysis
(GSEA) [14] to assess which gene set or pathway was sig-
nificant. The method derives its power by focusing on
gene sets, that is, groups of genes that share common bio-
logical function, chromosomal location, or regulation.
GSEA used a collection of gene sets from the Molecular
Signatures Database (MSigDB), which was divided into
five major collections. In our work, we used C2 catalog of
functional gene sets, which collected the signalling path-
way information from the publicly available, manually
curated databases and experimental studies.
Furthermore, we performed MAPE, a systematic
approach improved by Shen [4] for pathway enrichment
analysis. It provides a more robust and powerful tool by
combining statistical significance across studies, and
obtains more consistent results.
Overlapping analysis at different levels
The overlapping analysis was performed between two-pair
datasets on the same stage. For every pair of datasets, the
number of significant genes, or pathways/gene sets was
labelled as g1 in dataset-1, as g2 in dataset-2, respectively.
The overlapping percentage between two datasets was
designated as the number of overlapping genes/pathways
divided by the number of genes, or pathways/gene sets in
the union of g1 and g2. It can be calculated as follows:
Overlapping percentage =
s
g1 + g2 - s
× 100%.
Additional material
Additional file 1: GeneGO Ontology classification of 187 enriched
pathways from the miRNAs expression profiles. The Gantt bars
described that these pathways could be divided into 26 GeneGO’s
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Ontology categories. For example, 70 pathways were associated with
Development, 16 pathways were relevant to Immune response, and 12
pathways were related to G-protein signalling and so on.
Additional file 2: The GeneGO’s pathways overlapped by the omics
data.
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